Piper Sandler Maintains Overweight on Edwards Lifesciences (EW) Ahead of PARTNER 3 7-Year Results

Edwards Lifesciences Corporation (NYSE:EW) ranks among the best medical device stocks to invest in. Piper Sandler maintained its Overweight rating and $90 price target for Edwards Lifesciences Corporation (NYSE:EW) on October 7, ahead of the expected 7-year findings from Edwards’ PARTNER 3 study, which is set to be presented on October 27 at the Transcatheter Cardiovascular Therapeutics (TCT) conference.

With follow-up spanning ten years, Edwards’ historic PARTNER 3 trial compares surgical aortic valve replacement (SAVR) with its Sapien 3 transcatheter aortic valve replacement (TAVR) in low-risk patients.

According to Piper Sandler, upcoming data will likely show that TAVR is not inferior to SAVR on these endpoints, which could render the findings a “non-event with minimal commercial implications.”

Edwards Lifesciences Corporation (NYSE:EW) develops and sells patient-focused medical innovations, including transcatheter heart valves and hemodynamic monitoring systems for the treatment of structural heart disease and critical care.

While we acknowledge the potential of EW to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than EW and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.